383 related articles for article (PubMed ID: 8857999)
21. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Wang Y; Becker D
Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
[TBL] [Abstract][Full Text] [Related]
24. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ
Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335
[TBL] [Abstract][Full Text] [Related]
25. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV.
Olshan AF; Weissler MC; Pei H; Conway K; Anderson S; Fried DB; Yarbrough WG
Oncogene; 1997 Feb; 14(7):811-8. PubMed ID: 9047388
[TBL] [Abstract][Full Text] [Related]
26. Genetic alterations associated with glioma progression.
Kleihues P; Lübbe J; Watanabe K; von Ammon K; Ohgaki H
Verh Dtsch Ges Pathol; 1994; 78():43-7. PubMed ID: 7534015
[TBL] [Abstract][Full Text] [Related]
27. p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan.
Mangold KA; Takahashi H; Brandigi C; Wada T; Wakui S; Furusato M; Boyd J; Chandler FW; Allsbrook WC
J Urol; 1997 Mar; 157(3):1117-20. PubMed ID: 9072554
[TBL] [Abstract][Full Text] [Related]
28. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity.
Kinoshita I; Dosaka-Akita H; Mishina T; Akie K; Nishi M; Hiroumi H; Hommura F; Kawakami Y
Cancer Res; 1996 Dec; 56(24):5557-62. PubMed ID: 8971152
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
[TBL] [Abstract][Full Text] [Related]
30. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt EE; Ichimura K; Reifenberger G; Collins VP
Cancer Res; 1994 Dec; 54(24):6321-4. PubMed ID: 7987821
[TBL] [Abstract][Full Text] [Related]
31. Increased p16 levels correlate with pRb alterations in human urothelial cells.
Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C
Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615
[TBL] [Abstract][Full Text] [Related]
32. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
33. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
He J; Allen JR; Collins VP; Allalunis-Turner MJ; Godbout R; Day RS; James CD
Cancer Res; 1994 Nov; 54(22):5804-7. PubMed ID: 7954404
[TBL] [Abstract][Full Text] [Related]
34. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.
Luca M; Xie S; Gutman M; Huang S; Bar-Eli M
Oncogene; 1995 Oct; 11(7):1399-402. PubMed ID: 7478563
[TBL] [Abstract][Full Text] [Related]
35. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
[TBL] [Abstract][Full Text] [Related]
36. Cell cycle regulators in bladder cancer: relationship to schistosomiasis.
Eissa S; Ahmed MI; Said H; Zaghlool A; El-Ahmady O
IUBMB Life; 2004 Sep; 56(9):557-64. PubMed ID: 15590562
[TBL] [Abstract][Full Text] [Related]
37. HPV infection and the alterations of the pRB pathway in oral carcinogenesis.
Lim KP; Hamid S; Lau SH; Teo SH; Cheong SC
Oncol Rep; 2007 Jun; 17(6):1321-6. PubMed ID: 17487385
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
Wiest JS; Franklin WA; Otstot JT; Forbey K; Varella-Garcia M; Rao K; Drabkin H; Gemmill R; Ahrent S; Sidransky D; Saccomanno G; Fountain JW; Anderson MW
Cancer Res; 1997 Jan; 57(1):1-6. PubMed ID: 8988029
[TBL] [Abstract][Full Text] [Related]
39. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas.
Kirla RM; Haapasalo HK; Kalimo H; Salminen EK
Cancer; 2003 Feb; 97(3):644-8. PubMed ID: 12548606
[TBL] [Abstract][Full Text] [Related]
40. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma.
Okami K; Reed AL; Cairns P; Koch WM; Westra WH; Wehage S; Jen J; Sidransky D
Oncogene; 1999 Jun; 18(23):3541-5. PubMed ID: 10376532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]